U.S. markets open in 3 hours 57 minutes
  • S&P Futures

    4,078.25
    -3.00 (-0.07%)
     
  • Dow Futures

    34,546.00
    -53.00 (-0.15%)
     
  • Nasdaq Futures

    12,019.00
    -23.25 (-0.19%)
     
  • Russell 2000 Futures

    1,891.10
    +3.60 (+0.19%)
     
  • Crude Oil

    81.10
    +0.55 (+0.68%)
     
  • Gold

    1,793.40
    +33.50 (+1.90%)
     
  • Silver

    22.30
    +0.52 (+2.38%)
     
  • EUR/USD

    1.0443
    +0.0035 (+0.33%)
     
  • 10-Yr Bond

    3.7030
    0.0000 (0.00%)
     
  • Vix

    20.88
    -1.01 (-4.61%)
     
  • GBP/USD

    1.2147
    +0.0086 (+0.71%)
     
  • USD/JPY

    136.4150
    -1.6650 (-1.21%)
     
  • BTC-USD

    17,099.37
    +208.22 (+1.23%)
     
  • CMC Crypto 200

    405.09
    +4.40 (+1.10%)
     
  • FTSE 100

    7,580.26
    +7.21 (+0.10%)
     
  • Nikkei 225

    28,226.08
    +257.09 (+0.92%)
     

Is This Unknown Growth Stock a Buy After Its Blast Off?

Alnylam Pharmaceuticals' (NASDAQ: ALNY) stock went vertical in the past month -- up over 50% -- and there might be even more growth on the way. Sales of its top-earning medicines are booming, and breakthroughs in clinical trials have added to the enthusiasm. Alnylam has a small handful of medicines on the market, led by its drugs Onpattro and Amvuttra, which are intended to treat peripheral neuropathy caused by hereditary transthyretin amyloidosis (ATTR), which is a rare but deadly and progressively worsening heart disease.